Replacement Therapy with Blood Products in People Living with HIV

Overview

Journal Trop Med Infect Dis

Specialty Infectious Diseases

Date 2024 Sep 27

PMID 39330902

Authors

Mihaela Cristina Olariu

Mihaela Adela Iancu

Mihai Hristu Olariu

Victoria Arama

Madalina Simoiu

Miruna Maria Cruceru

Ecaterina Constanta Barbu

Paul Balanescu

Mihai Lazar

Affiliations

Soon will be listed here.

Abstract

Cytopenias or coagulation deficiencies can occur in people living with HIV (PLWH). The severity of these disorders is influenced by the low levels of CD4+ lymphocytes, viral load, and the stage of viral infection. The aim of our retrospective observational study was to determine the frequency of cytopenias and coagulation deficiencies in PLWH as well as the need for replacement therapy with blood products. We sought to determine whether there is an association between severe anemia or thrombocytopenia (requiring replacement therapy) and CD4+T lymphocyte levels. All 29 patients were critically ill, with 27 out of 29 (93%) in advanced stages of HIV disease and 23 out of 29 (79%) having CD4+ lymphocyte counts below 200 cells/microL. Most patients were either late presenters (45%) or had been lost to follow-up (41%). In addition to HIV infection, various conditions that could alter hematologic parameters were associated, including co-infections with hepatitis viruses, tuberculosis at various sites, malignant diseases, sepsis, SARS-CoV-2 infection, or other opportunistic infections. No significant correlation was found between severe anemia or severe thrombocytopenia or coagulation deficiencies and the CD4+T lymphocyte count. Our data suggest that these hematological disorders in patients with advanced HIV infection are more likely to be associated comorbidities rather than the HIV infection per se.

References

Flores J, Liang Y, Ketchum N, Turner B, Bullock D, Villarreal R . Prescription Opioid Use is Associated with Virologic Failure in People Living with HIV. AIDS Behav. 2017; 22(4):1323-1328. DOI: 10.1007/s10461-017-1842-2. View

Choi S, Kim I, Kim N, Lee S, Choi Y, Bae J . Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia. Korean J Hematol. 2012; 46(4):253-7. PMC: 3259517. DOI: 10.5045/kjh.2011.46.4.253. View

Olariu M, Olariu C, Olteanu D . Thrombocytopenia in chronic hepatitis C. J Gastrointestin Liver Dis. 2010; 19(4):381-5. View

Gibellini D, Clo A, Morini S, Miserocchi A, Ponti C, Re M . Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol. 2013; 2(2):91-101. PMC: 3785048. DOI: 10.5501/wjv.v2.i2.91. View

Agegnehu C, Merid M, Yenit M . Predictors of Anemia Among Adult HIV Positive Patients on First-Line Antiretroviral Therapy in Northwest Ethiopia: A Retrospective Follow-Up Study. HIV AIDS (Auckl). 2021; 13:455-466. PMC: 8096420. DOI: 10.2147/HIV.S280338. View

Mayne E, Louw S . Good Fences Make Good Neighbors: Human Immunodeficiency Virus and Vascular Disease. Open Forum Infect Dis. 2019; 6(11):ofz303. PMC: 6847507. DOI: 10.1093/ofid/ofz303. View

Re M, Zauli G, Furlini G, Giovannini M, La Placa M . HIV-1 infection and hematologic picture. Microbiologica. 1991; 14(2):165-76. View

Volberding P, Levine A, Dieterich D, Mildvan D, Mitsuyasu R, Saag M . Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004; 38(10):1454-63. DOI: 10.1086/383031. View

Bosch N, Law A, Bor J, Myers L, Roubinian N, Liu V . Red Blood Cell Transfusion at a Hemoglobin Threshold of 7 g/dl in Critically Ill Patients: A Regression Discontinuity Study. Ann Am Thorac Soc. 2022; 19(7):1177-1184. PMC: 9278636. DOI: 10.1513/AnnalsATS.202109-1078OC. View

10.

Ronald P, Robertson J, Elton R . Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS. 1994; 8(3):339-43. DOI: 10.1097/00002030-199403000-00007. View

11.

Cines D, Blanchette V . Immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13):995-1008. DOI: 10.1056/NEJMra010501. View

12.

Plein L, Rittner H . Opioids and the immune system - friend or foe. Br J Pharmacol. 2017; 175(14):2717-2725. PMC: 6016673. DOI: 10.1111/bph.13750. View

13.

Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J . Late presentation of HIV infection: a consensus definition. HIV Med. 2010; 12(1):61-4. DOI: 10.1111/j.1468-1293.2010.00857.x. View

14.

Marchionatti A, Parisi M . Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. Int Health. 2020; 13(2):98-109. PMC: 7902680. DOI: 10.1093/inthealth/ihaa036. View

15.

Perkins M, Joseph S, Dittmer D, Mackman N . Cardiovascular Disease and Thrombosis in HIV Infection. Arterioscler Thromb Vasc Biol. 2022; 43(2):175-191. PMC: 10165851. DOI: 10.1161/ATVBAHA.122.318232. View

16.

Mocroft A, Lundgren J, Sabin M, Monforte A, Brockmeyer N, Casabona J . Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013; 10(9):e1001510. PMC: 3796947. DOI: 10.1371/journal.pmed.1001510. View

17.

Vishnu P, Aboulafia D . Haematological manifestations of human immune deficiency virus infection. Br J Haematol. 2015; 171(5):695-709. DOI: 10.1111/bjh.13783. View

18.

Krentz H, Auld M, Gill M . The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med. 2004; 5(2):93-8. DOI: 10.1111/j.1468-1293.2004.00193.x. View

19.

Assinger A . Platelets and infection - an emerging role of platelets in viral infection. Front Immunol. 2015; 5:649. PMC: 4270245. DOI: 10.3389/fimmu.2014.00649. View

20.

Chelariu A, Coman A, Lionte C, Gorciac V, Sorodoc V, Haliga R . The Value of Early and Follow-Up Elevated Scores Based on Peripheral Complete Blood Cell Count for Predicting Adverse Outcomes in COVID-19 Patients. J Pers Med. 2022; 12(12). PMC: 9781715. DOI: 10.3390/jpm12122037. View